Daewoong Co., Ltd. Overview
Daewoong Co. is the business holding company of one of South Korea's five largest traditional pharmaceutical groups. It controls Daewoong Pharmaceutical (52.29%), which in FY2025 posted record consolidated revenue of KRW 1,570.9 bn and operating profit of KRW 196.8 bn on the strength of three in-house products: the botulinum toxin Nabota (sold as Jeuveau in the US and Nuceiva in Europe), the P-CAB acid blocker Fexuclue, and the SGLT-2 inhibitor Envlo. It also owns 100% of Daewoong Bio, a high-margin generic and API maker with FY2025 revenue of KRW 641.3 bn, and indirectly controls HanAll Biopharma through Daewoong Pharmaceutical. Group consolidated revenue first exceeded KRW 2 tn in FY2025. The equity trades at a deep holding-company discount: at early-October 2026 prices, the market value of its Daewoong Pharmaceutical stake alone exceeded its own ex-treasury market capitalisation. The main swing factors are the Medytox trade-secret appeal, US tariffs on Korean pharmaceuticals, and how the company handles its 27.7% treasury stake under Korea's amended Commercial Act.
What the company does
| Subsidiary | Ownership | Business | FY2025 scale | Source |
|---|---|---|---|---|
| Daewoong Pharmaceutical Co., Ltd. (KOSPI 069620) | 52.29% direct (61.32% with related parties incl. Daewoong Foundation 8.62%) | Prescription drugs (ETC), OTC, Nabota toxin, digital healthcare, global sales; parent of HanAll Biopharma | Consolidated revenue KRW 1,570.9 bn; OP KRW 196.8 bn | [S11][S27][S28] |
| Daewoong Bio Co., Ltd. | 100% | Finished generics (e.g. Gliatamin, a choline alfoscerate product), APIs (UDCA), contract manufacturing | Revenue KRW 641.3 bn; OP KRW 73.9 bn | [S29] |
| HanAll Biopharma Co., Ltd. (KOSPI) | ≈30% held via Daewoong Pharmaceutical | Specialty pharma plus FcRn antibody R&D (batoclimab, IMVT-1402) partnered with Immunovant | Revenue KRW 155.2 bn; operating loss KRW 0.9 bn | [S30][S31] |
| Daewoong Development | Subsidiary | Real-estate rental and supply | — | [S1] |
| IDS&Trust | Subsidiary | Communication-related devices / IT | — | [S1] |
| Daewoong Life Science | Subsidiary | Food processing and sales | — | [S1] |
| Pampaeg | Subsidiary | Packaging of quasi-drugs | — | [S1] |
| Daewoong Management Development Institute | Subsidiary | Management and industrial training | — | [S1] |
| Daewoong Therapeutics | Group R&D affiliate | Microneedle drug-delivery platform (licensed to Daewoong Pharmaceutical in Feb 2026) | — | [S32] |
| Healience; Daewoong Pharma Philippines; Daewoong Pharmaceutical (Thailand); Daewoong Pharmaceutical (Indonesia); Daewoong Pharmaceutical Hongkong (intermediate holding); Daewoong Pharmaceutical Japan | Subsidiaries of Daewoong Pharmaceutical | Health services and overseas sales or holding vehicles | — | [S27] |
Daewoong Co. describes itself in its filings as the holding company of a group whose stated aim is to lead improvements in quality of life as a global healthcare group, and says it provides investment and management services to its subsidiaries [S40][S41]. It is a "business holding company" (사업지주회사): it also runs some businesses directly. Aggregator summaries of its filings list the manufacture and sale of APIs and finished drugs, real-estate leasing, a corporate training centre, research services on lifestyle-disease prevention, and facilities management [S37][S3]. Holding-company standalone revenue was roughly KRW 74 bn in FY2025 according to a recruitment-data aggregator [S19b], which is under 4% of consolidated revenue. The economic value of the company is therefore almost entirely the value of its subsidiaries.
Principal subsidiaries and what they do:
CG Bio (시지바이오), a regenerative-medicine company often described as a "Daewoong Group affiliate," is not a subsidiary of Daewoong Co. It is owned through A-Hana, which in turn is 55.84% held by Bluenet, a family company controlled by Yoon Jae-seung [S33][S34]. Its sale matters to Daewoong Co. shareholders mainly through governance and possible owner-level use of the proceeds.
Business and revenue model
Product sales dominate: Revenue is overwhelmingly product revenue: prescription drugs, OTC products and toxin sales. Daewoong Pharmaceutical says about 60% of its prescription sales now come from its own products rather than in-licensed products [S11]. That matters because in-licensed (co-promoted) products carry much lower gross margins.
Export and partnership revenue: Nabota is sold abroad largely through distribution and supply partners, the main one being Evolus in the US. Daewoong supplies finished product and receives supply revenue plus milestones. About 84% of Nabota revenue is exports [S12][S17].
Licensing revenue: Out-licensing generates upfront payments and milestones. Examples: bersiporocin Greater China rights to CS Pharmaceuticals (2023, up to USD 336 m); DWP213388 to Vitalli Bio (2023, up to USD 477 m); Envlo Latin America to Moksha8 (2023, USD 84.36 m) [S49]. These are lumpy and not separately disclosed in group revenue.
Services and digital healthcare: Daewoong Pharmaceutical's digital-healthcare unit sells or distributes connected devices and services, including the thynC smart-ward monitoring system, the FreeStyle Libre CGM, the mobiCARE wearable ECG, the CART BP ring blood-pressure monitor and the WISKY AI retinal tool. Its revenue was KRW 36.3 bn for 9M2025, then KRW 17.0 bn in Q1 2026 and KRW 15.7 bn in Q2 2026 [S12][S13][S14].
Real estate and other: Rental and training services sit at the holding company and its smaller subsidiaries. They are immaterial to group profit.
Subscription model: None disclosed.
Value-chain position, customers and end-markets
The group is vertically integrated. It produces APIs (Daewoong Bio's UDCA), formulates finished dosage forms (Hyangnam and Osong plants), produces biologics (Nabota at Hyangnam), sells to hospitals and clinics through its own sales force (ETC), reaches pharmacies and retail (OTC, including a channel into the Daiso variety-store chain), and exports through licensees. Customers are:
-
Korean hospitals, clinics and pharmacies, reimbursed by the National Health Insurance Service (NHIS).
-
Aesthetic practices worldwide, reached through partners (Evolus in the US and Europe; distributors in Latin America, the Middle East and North Africa, and Southeast Asia).
-
Licensees and pharma partners (e.g. Sun Pharma in India for Fexuclue).
-
Consumers through OTC and health-food channels.
End-markets: Korean prescription market (gastroenterology, metabolic/diabetes, liver, CNS); global aesthetic neurotoxins; and emerging-market GI and diabetes markets.
Independent characterisation
Daewoong Co. is best understood as a levered claim on Daewoong Pharmaceutical's export toxin franchise plus a cash-generating domestic generics engine (Daewoong Bio), packaged inside a family-controlled holding structure. Since 2023 the operating story has improved clearly: Daewoong Pharmaceutical's operating margin rose from 7.5% in FY2022 to 12.5% in FY2025 as high-margin Nabota exports grew from KRW 145.3 bn to KRW 228.9 bn (derived from [S11][S28][S23]). The equity story has worsened over the same period. The share price is down about 30% year-to-date to early October 2026. The main pressures are an unresolved trade-secret case with Medytox (claim raised tenfold in August 2026), an unresolved plan for the 27.7% treasury stake, and the perception that the founding family is pursuing value creation outside the listed company (the CG Bio sale).
Strategy
Stated strategy (paraphrased from management statements)
Holding-company level (Daewoong Co.): At the March 2025 AGM, CEO Yoon Jae-chun described a cycle in which innovative new drugs change their markets and fund more R&D and new growth engines. He named new-drug development, formulation technology, strategic investment in AI and digital healthcare, and global talent as the priorities [S9]. The group's long-standing vision is to be a global healthcare group leading quality-of-life improvement [S40].
Daewoong Pharmaceutical: The headline vision is "1 product, 1 trillion" (1품 1조): building single products that reach KRW 1 tn in annual sales [S20][S94]. FY2026 priorities announced with FY2025 results [S11b]:
-
Global expansion: Fexuclue into China, Latin America and the Middle East; Nabota into the EU big-five.
-
Realising R&D value, with a focus on obesity and oncology.
-
New growth engines through a "total healthcare ecosystem" linking wearables and data.
Nabota: Grow to KRW 500 bn in annual sales by 2030 and become a "total aesthetics" company (skin boosters, fillers, cosmetics, recombinant toxin) [S24][S67].
Strategic initiatives in the last 24 months
| Date | Initiative | Detail | Source |
|---|---|---|---|
| 2024–2027 | Nabota plant 3 | Dedicated toxin plant; total capacity 16 m vials a year from 2027 | [S24] |
| 2024–ongoing | Magok C&D Center | About KRW 163.7 bn R&D hub in Seoul | [S57b] |
| 2025–2026 | Digital healthcare scale-up | thynC: about 17,000 beds and about 200 hospitals. Extensions into AI endoscopy, AI medical records, home care | [S14][S13][S73] |
| 2,025 | OTC channel diversification | Daiso retail entry; OTC integrated with health-functional foods | [S11b] |
| Q1 2026 | ETC distribution-channel streamlining | Simplified wholesaler network. Temporary Q1 revenue and OP hit | [S80] |
| Feb 2026 | Obesity microneedle platform | Exclusive global licence from Daewoong Therapeutics for microneedle patches, incl. GLP-1 (semaglutide) patch formulations | [S32][S98] |
| May 2026 | IBD pipeline | INV-008 licensed in from Innovo Therapeutics (KRW 662.5 bn total; KRW 6.5 bn upfront) | [S99] |
| 2025–2026 | Fexuclue lifecycle | New indications (gastric-ulcer Phase 3 IND, Sep 2026), multi-country Phase 3 with Indonesia | [S39][S68] |
| Dec 2025–Jan 2026 | Holding-company strategic equity | Treasury-share swaps into Kwangdong (4.4%) and U2Bio (15%, in-vitro diagnostics and medical IT; described as a digital-healthcare move) | [S41][S42] |
| 2,025 | ESG programme | "CARE for People and Planet" framework at Daewoong Pharmaceutical | [S62] |
Medium-term targets and guidance
| Target | Value | Owner | Source |
|---|---|---|---|
| Daewoong Pharmaceutical FY2026 guidance (maintained May 2026) | Revenue about KRW 1.5 tn; OP about KRW 220 bn (basis per Kyobo note; likely separate) | Daewoong Pharmaceutical | [S80] |
| Nabota 2030 | KRW 500 bn annual sales | Daewoong Pharmaceutical | [S24] |
| Envlo | 30 countries by 2030 | Daewoong Pharmaceutical | [S69] |
| Market capitalisation | KRW 5 tn in 3 years; KRW 20 tn in 10 years (stated at appointment, Mar 2024) | Park Seong-soo | [S92] |
| Daewoong Co. | No quantitative financial or shareholder-return targets found in retrieved sources | — | — |
Products & Services
Product-level revenue is disclosed only for flagship brands. Pricing is set by the NHIS for reimbursed drugs and is not separately disclosed.
Aesthetics / Biologics (Daewoong Pharmaceutical, Nabota division)
| Product | Description | Target customer | Launch / latest | Commercial data | Source |
|---|---|---|---|---|---|
| Nabota (Korea and RoW) / Jeuveau (US) / Nuceiva (EU) | Botulinum toxin type A (prabotulinumtoxinA). Daewoong calls it a high-purity toxin. Approved by the FDA, EMA and Health Canada | Aesthetic clinics (glabellar lines); therapeutic indications being pursued in some markets | Korea 2014; US FDA 2019 | FY2024 KRW 186.4 bn (+27%), about 84% exported; FY2025 KRW 228.9 bn (+19% company basis); Q2 2026 KRW 103.4 bn (exports KRW 94.1 bn, +54.2%). Cumulative sales passed KRW 1 tn at 30 Jun 2026. Approved in 69 countries, partners in about 80. Jeuveau holds more than 14% of the US aesthetic toxin market (Evolus) | [S12][S23][S24][S16][S66] |
| Next-generation aesthetics (pipeline) | Biodegradable collagen-stimulating skin booster, bio-material filler, medical-cosmetic platform, recombinant toxin | Aesthetic market | In development | 2030 Nabota franchise target: KRW 500 bn annual sales | [S24][S67] |
Prescription (ETC) — in-house new drugs
| Product | Description | Target customer | Launch | Commercial data | Source |
|---|---|---|---|---|---|
| Fexuclue (fexuprazan) | Potassium-competitive acid blocker (P-CAB) for erosive oesophagitis and GERD; Korean new drug #34. Positioned against PPIs on onset, half-life and dosing convenience | GI specialists and primary care | Korea Jul 2022 | Product sales KRW 102.0 bn FY2024, KRW 94.5 bn FY2025, KRW 19.2 bn Q1 2026 (−29.8% YoY because of distributor destocking). Co-promoted with Chong Kun Dang. Export contracts in 30 countries and approvals in 16 (incl. China, Indonesia) as of Apr 2026. India launch with Sun Pharma Apr 2025. Gastric-ulcer Phase 3 IND approved Sep 2026 | [S18][S55][S68][S59][S39] |
| Envlo (enavogliflozin) | SGLT-2 inhibitor for type 2 diabetes; Korean new drug #36; mono and combination forms (incl. metformin and DPP-4 combinations) | Diabetologists and primary care | Korea 2023 | KRW 11.6 bn FY2024; KRW 12.3 bn FY2025. Filed or entered in 19 countries (Apr 2025); target 30 countries by 2030. Export contracts with 8 Latin American countries; Middle East partnership with Arcera | [S18][S69][S3] |
| Ursa (UDCA) family | Ursodeoxycholic acid for liver function. Listed in Korean gastric-cancer guidelines for preventing gallstones after gastrectomy | Hepatology, GI, OTC | 1961; soft capsule 1974 | Company-reported KRW 96.2 bn (FY2024, includes OTC Ursa); Kiwoom product series KRW 88.7 bn FY2024 and KRW 92.9 bn FY2025 | [S12][S18] |
| Other ETC portfolio | Co-promoted and in-licensed brands (historically including Forxiga, Lixiana, Crestor and Gemigliptin co-promotion). | Hospitals and clinics | Various | Daewoong reports outpatient prescriptions above KRW 1 tn for two consecutive years (2023–24) | [S70][S71] |
OTC & consumer health
| Product | Description | Notes | Source |
|---|---|---|---|
| Ursa (OTC strengths), Impactamin (vitamin B), EasyN6 (analgesic), Bearse (digestive), C-Cold | Leading Korean OTC brands | OTC division revenue KRW 162.6 bn in FY2025 on the company's presentation basis. Growth helped by Daiso retail distribution | [S11b][S72] |
| Health-functional foods | Supplements, now managed alongside OTC | Linked to OTC from 2025 | [S11b] |
Digital healthcare (Daewoong Pharmaceutical)
| Product | Description | Data | Source |
|---|---|---|---|
| thynC | Wearable-based smart-ward patient monitoring, developed with AI med-tech firm Seers Technology. First Korean digital-health device to obtain a remote-monitoring reimbursement code (EX871) | About 17,000 beds installed (6,000 added in Q1 2026); about 200 hospitals incl. Hanyang University and Chonnam National University hospitals. Revenue is recognised with a lag of about 6 months | [S12][S14][S73] |
| FreeStyle Libre (distributed) | Continuous glucose monitor | — | [S12] |
| mobiCARE | Wearable ECG | — | [S12] |
| CART BP | Ring-type continuous blood-pressure monitor | — | [S12] |
| WISKY | AI diagnostic aid for blinding retinal disease | — | [S12] |
| AI endoscopy, AI medical records, home care | Expansion areas named in Q2 2026 | Division revenue: KRW 17.0 bn Q1 2026, KRW 15.7 bn Q2 2026 (+27% YoY) | [S13] |
Daewoong Bio (100% subsidiary)
| Product | Description | Data | Source |
|---|---|---|---|
| Gliatamin | Choline alfoscerate (cognitive-function agent) | Prescriptions approaching KRW 200 bn a year. Close to 30% of Daewoong Bio revenue in 2024 | [S29][S74] |
| Beacept, rabeprazole low-dose, donepezil–memantine combination, orally dissolving migraine product | Branded generics | Daewoong Bio ranked 6th in the Korean outpatient prescription market in H1 2025 | [S75] |
| UDCA API | Ursodeoxycholic acid API (domestic and export) | Historic core API business | [S75] |
| Global CMO | Contract manufacturing | Daewoong Bio described as having entered global CMO | [S9] |
HanAll Biopharma (≈30% via Daewoong Pharmaceutical)
| Product / asset | Description | Data | Source |
|---|---|---|---|
| Biotop | Probiotic drug | KRW 23.8 bn sales (2025); 2026 target about KRW 30 bn | [S30] |
| Hairgro (finasteride 1 mg) and hair-loss line | No.1 share among finasteride 1 mg generics | Hair-loss line above KRW 10 bn | [S30] |
| Eligard | Leuprolide (prostate cancer, precocious puberty) | — | [S30] |
| Batoclimab (HL161BKN / IMVT-1401) | Anti-FcRn antibody partnered with Immunovant/Roivant | Met primary endpoint in myasthenia gravis Phase 3. Both thyroid eye disease (TED) Phase 3 trials failed their primary endpoints (2 Apr 2026). HanAll had been preparing Japan commercialisation | [S30][S31][S76] |
| IMVT-1402 (HL161ANS, imeroprubart) | Next-generation FcRn antibody | Phase 2 or registrational studies in 6 indications. Graves' disease registrational data in 2027; rheumatoid-arthritis pivotal early data and cutaneous lupus PoC in 2026 | [S30][S77] |
| Tanfanercept | TNF inhibitor for dry eye | VELOS-4 Phase 3 topline in 2026 | [S30] |
| HL192 | Nurr1 activator for Parkinson's | Next clinical stage targeted | [S30] |
Financial Narrative
Income statement
Sources: Revenue and OP FY2021 [S22], FY2022 [S21], FY2023 revenue [S20], FY2024 [S9], FY2025 [S10]. FY2023 OP, gross profit and FY2021–22 controlling NI and EPS from an aggregator [S5a]. FY2023–24 NI and EPS from the KRX quarterly report summary [S40]. FY2025 controlling NI and EPS from an aggregator [S5a], cross-checked against 9M2025 controlling NI of KRW 105.2 bn [S40]. DPS [S9][S45][S2]. Margins and growth derived (FY2021 growth uses FY2020 revenue of KRW 1,355.3 bn [S22b]). The Paasa aggregator shows FY2025 OP of KRW 260.5 bn against the company's KRW 262.05 bn; the company figure is used. FY2025 gross profit is shown by aggregators only as "≈KRW 1.1 tn" (about 53% gross margin on a trailing basis [S5b]); it is left blank in the chart table because a precise figure was not available.
Revenue CAGR FY2021–FY2025: 8.2% (derived).
Commentary.
Revenue: The group has grown every year, but the rate halved after FY2022 (about 12% in FY2021–22, about 7% in FY2023–25). Growth now comes mostly from Nabota exports, Daewoong Bio's generics and Fexuclue/Envlo volume. Domestic ETC price cuts weigh on it.
Operating profit: FY2024 was the peak at KRW 281.9 bn and a 14.6% margin [S9]. The FY2025 decline to KRW 262.05 bn (−7.0%) [S10] happened despite Daewoong Pharmaceutical's 33% OP growth, and is explained by weaker Daewoong Bio and HanAll profits plus an unexplained residual.
Net income: Net income is volatile because of below-the-line items at Daewoong Pharmaceutical. In FY2024 Daewoong Pharmaceutical's net income fell to KRW 23.3 bn, in part from an impairment of previously capitalised Fexuclue clinical costs after a trial redesign (reported in 2024 [S78]) and litigation provisions. It recovered to KRW 192.9 bn in FY2025, helped by other income of KRW 59.1 bn, partly one-off [S79]. The group's FY2025 net income of KRW 222.37 bn (+222.9%) reflects that rebound [S10].
EBITDA: Not disclosed in retrieved sources. A US valuation aggregator puts last-fiscal-year EBITDA at about USD 231 m [S4]; it is not used in the chart table because of currency and definition uncertainty.
Recent quarterly trajectory
Sources: Daewoong Co. quarterly revenue from Google Finance [S2][S36]. Q1 2025 is derived from the FY2025 total. Q1 2026 revenue (+2.3% YoY) is confirmed by [S38]. Daewoong Pharmaceutical quarterly data from company releases and broker reviews [S13][S80][S81]. Q3 2025 is derived from the full-year total.
Q1 2026 was weak because Daewoong Pharmaceutical deliberately streamlined its ETC distribution channels, which cut shipments; consolidated OP fell 42.6% [S80]. Q2 2026 was a record quarter: consolidated revenue KRW 448.5 bn (+10.6%) and OP KRW 68.1 bn (+17.7%), above consensus of KRW 424.4 bn and KRW 63.1 bn [S13][S81]. Part of this was Evolus building inventory early ahead of a US tariff on Korean patented pharmaceuticals effective 29 Sep 2026 [S14]. Daewoong Co.'s Q2 2026 revenue of KRW 570.8 bn was also a record. Its Q2 2026 OP is not company-confirmed in the sources; Google Finance line items imply about KRW 76.6 bn (derived).
Balance sheet
Sources: Valueline consolidated balance sheet [S82]; KRX quarterly-report summary for FY2023–24 current liabilities [S40]. FY2025 total assets and liabilities are from Valueline's 2025/12 column; FY2025 equity is derived. Latest (31 Mar 2026): total assets KRW 3,407.7 bn, liabilities KRW 1,554.6 bn, equity KRW 1,853.1 bn, cash KRW 259.7 bn [S82]. 30 Sep 2025: total assets KRW 3,096.5 bn, current liabilities KRW 784.1 bn, equity KRW 1,628.6 bn [S40].
- Total debt (short/long split), net debt, goodwill and intangibles, working capital: not disclosed in the sources retrieved for the holding company. Daewoong Pharmaceutical's own net debt was estimated at KRW 355 bn (FY2023) and KRW 576 bn (FY2024) by Samsung Securities. Its liabilities-to-equity ratio was about 125% at Q3 2025, after corporate bond issuance of KRW 195 bn (2024) and KRW 140 bn (2025) to fund the third Nabota plant and the Magok C&D centre [S83].
Holding company standalone (separate) balance sheet: total assets KRW 415.7 bn (FY2021), 467.0 (FY2022), 514.9 (FY2023), 543.9 (FY2024), 547.0 (Q3 2025). Liabilities KRW 50.5 bn at FY2024. The separate liabilities-to-equity ratio was 9.3% at Q3 2025 [S84][S40]. The parent itself carries almost no debt; leverage sits at Daewoong Pharmaceutical.
Balance-sheet commentary. Group assets grew by about KRW 1.07 tn between FY2022 and FY2025, while liabilities grew by about KRW 585 bn, funded largely by subsidiary bond issuance for capex. The current ratio fell from about 1.33 (FY2024, derived) to 1.01 in June 2026 per an aggregator [S85]. That is the lowest in ten years, reflecting bond maturities moving into current liabilities and capex drawdowns. It is a liquidity watch-point, not a solvency concern, given the parent's net cash and dividend inflows.
Cash flow: notes and sources
Sources: OCF from Paasa [S5a] and Stoxray [S5c] (consistent). FY2025 dividends are the declared total for FY2025 (KRW 8.29 bn), paid in 2026 [S45]. FY2023 buyback: Daewoong Co. bought KRW 10 bn of treasury shares in July 2023 [S20]. Known major capex at Daewoong Pharmaceutical: about KRW 101.4 bn for the new Nabota plant and KRW 163.7 bn for the Magok C&D centre [S57b].
Ratios
All ratios are derived–6.3. ROE and ROA use net income including minorities over average equity and assets. Aggregators show trailing ROE of 14.5%–16.3% in 2026 [S38][S36]. ROIC, net debt/EBITDA, interest coverage and cash conversion cycle for the holding company could not be computed from the data retrieved. Daewoong Pharmaceutical's interest coverage was 21.2x (FY2024) per Samsung Securities [S83].
Trend synthesis. Profitability recovered in FY2025, but mostly below the operating line. Asset turnover is falling as capital is deployed in plants that are not yet producing (the new Nabota plant starts in 2027). Payout is extremely low at about 5% of controlling profit, and this is the central capital-allocation criticism of the stock.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Daewoong Co. consolidated revenue | 1,813.8 | 1,936.9 | 2,068.6 |
Daewoong Pharmaceutical consolidated revenue | 1,375.3 | 1,422.7 | 1,570.9 |
Daewoong Bio revenue | 511.7 | 579.7 | 641.3 |
HanAll Biopharma revenue (inside Daewoong Pharmaceutical) | 134.9 | 138.9 | 155.2 |
Operating profit by entity (KRW Bn)
| Operating profit by entity (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Daewoong Co. consolidated OP | 195.9 | 281.9 | 262.1 |
Daewoong Pharmaceutical consolidated OP | 122.6 | 147.9 | 196.8 |
Daewoong Bio OP | 60.8 | 80.5 | 73.9 |
HanAll Biopharma OP | — | — | -0.9 |
OP margin by entity (%)
| OP margin by entity (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Daewoong Co. consolidated | 10.8 | 14.6 | 12.7 |
Daewoong Pharmaceutical consolidated | 8.9 | 10.4 | 12.5 |
Daewoong Bio | 11.9 | 13.9 | 11.5 |
Revenue by Segment
| Division (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ETC (prescription) | 872.5 | 860.5 | 894.2 |
OTC (incl. health-functional foods from 2025 presentation) | 115.2 | 133.3 | 162.6 |
Nabota (botulinum toxin, domestic + export) | 145.3 | 186.4 | 228.9 |
Other separate (global, digital healthcare, other; derived residual) | 89.0 | 85.2 | 105.3 |
Separate-company revenue | 1,222.0 | 1,265.4 | 1,391.0 |
Consolidation and subsidiaries (derived: consolidated minus separate) | 153.3 | 157.3 | 179.9 |
Consolidated revenue | 1,375.3 | 1,422.7 | 1,570.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansDivision YoY growth (%)
| Division YoY growth (%) | FY2024 | FY2025 |
|---|---|---|
ETC | -1.4 | 3.9 |
Nabota | 28.3 | 22.8 |
Consolidated revenue | 3.4 | 10.4 |
Share of Daewoong Pharmaceutical consolidated revenue (%)
| Share of Daewoong Pharmaceutical consolidated revenue (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ETC | 63.4 | 60.5 | 56.9 |
Nabota | 10.6 | 13.1 | 14.6 |
OTC | 8.4 | 9.4 | 10.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 1,511.4 | 1,697.3 | 1,813.8 | 1,936.9 | 2,068.6 |
Revenue growth YoY (%) | 11.5 | 12.3 | 6.9 | 6.8 | 6.8 |
Gross profit (KRW Bn) | 763.2 | 899.7 | 931.2 | — | — |
Operating profit (KRW Bn) | 182.6 | 207.3 | 195.9 | 281.9 | 262.1 |
Net income incl. minorities (KRW Bn) | — | — | 191.4 | 68.9 | 222.4 |
Net income to controlling shareholders (KRW Bn) | 78.7 | 102.6 | 152.7 | 57.9 | 175.1 |
EPS basic (KRW) | 1,894.69 | 2,466.88 | 3,692 | 1,416 | 4,280 |
Dividend per share (KRW) | — | — | 100 | 200 | 200 |
Gross margin (%) | 50.5 | 53.0 | 51.3 | — | — |
Operating margin (%) | 12.1 | 12.2 | 10.8 | 14.6 | 12.7 |
Net margin, controlling (%) | 5.2 | 6.0 | 8.4 | 3.0 | 8.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Daewoong Co. revenue (KRW Bn) | 481.7 | 528.4 | 542.2 | 516.3 | 492.7 | 570.8 |
Daewoong Pharmaceutical consolidated revenue (KRW Bn) | 351.6 | 405.4 | 416.8 | 397.1 | 377.8 | 448.5 |
Daewoong Pharmaceutical consolidated OP (KRW Bn) | 38.3 | 57.9 | 57.2 | 43.4 | 22.2 | 68.1 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 2,158.9 | 2,359.3 | 2,720.7 | 3,232.2 |
Current assets (KRW Bn) | 954.0 | 862.5 | 953.7 | 1,032.4 |
Cash and cash equivalents (KRW Bn) | 190.4 | 161.7 | 191.5 | 255.9 |
Short-term financial assets (KRW Bn) | 130.3 | 79.8 | 62.5 | 26.4 |
Current liabilities (KRW Bn) | — | 691.0 | 716.2 | — |
Total liabilities (KRW Bn) | 879.4 | 922.5 | 1,218.2 | 1,464.8 |
Total equity incl. minorities (KRW Bn) | 1,279.5 | 1,436.8 | 1,502.5 | 1,767.4 |
Liabilities / equity (%) | 68.7 | 64.2 | 81.1 | 82.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansDividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 133.2 | 149.1 | 205.7 | 162.4 | 257.6 |
Dividends paid by Daewoong Co. (KRW Bn, approx.) | — | — | — | — | 8.3 |
Share buybacks (KRW Bn) | — | — | 10.0 | — | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average total equity (%) | — | 14.1 | 4.7 | 13.6 |
ROA on average total assets (%) | — | 8.5 | 2.7 | 7.5 |
Asset turnover (x) | — | 0.80 | 0.76 | 0.69 |
Current ratio (x) | — | 1.25 | 1.33 | — |
Liabilities / equity (x) | 0.69 | 0.64 | 0.81 | 0.83 |
Dividend payout on controlling NI (%) | — | — | — | 4.7 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
Nabota total revenue (KRW Bn) | 186.4 | 228.9 | 155.3 |
Nabota export revenue (KRW Bn, approx.) | 156.6 | — | — |
Nabota domestic revenue (KRW Bn, approx.) | 29.8 | — | — |
Export share of Nabota (%) | 84 | — | — |
Revenue by Region and Revenue by Region (%) (FY2024–FY2026 guidance (mid))
| Metric | FY2024 | FY2025 | FY2026 guidance (mid) |
|---|---|---|---|
Evolus total net revenue (USD Mn) | 265.4 | 297.2 | 332.0 |
Evolus international share of revenue (%) | 5 | 8 | — |
Share Price
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 20,350 | 20,650 | 21,600 | 22,050 |
Share Price & Returns
| Period | Return (%) |
|---|---|
Year-to-date 2026 (vs 31 Dec 2025) | -30.4 |
1 year (vs 30 Sep 2025 close of KRW 21,950) | -30.1 |
Since end-2022 (≈3.75 years) | -24.6 |
5 years (per Paasa, late Sep/Oct 2026) | -50.9 |
Valuation Multiples
| Multiple | Gross shares (58.14 m) | Ex-treasury (≈42.04 m) | Note |
|---|---|---|---|
Market cap (KRW Bn) | 891.9 | 644.9 | derived |
P/E on FY2025 controlling NI (x) | 5.1 | 3.7 | derived; aggregators show TTM 3.6–5.4 [S37][S38] |
P/B (x) | 0.78 | 0.56 | aggregators [S38][S39] |
EV/EBITDA, EV/Sales | Not computed (net debt not available) | — | — |
Dividend yield (%) | 1.3 | 1.3 | derived |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
DPS (KRW) | 100 | 200 | 200 |
Total dividend (KRW Bn) | — | — | 8.29 |
Valuation Snapshot
| Metric | Value |
|---|---|
Treasury ratio, end-2010 | 28.14% |
Treasury ratio, end-2020 | 28.54% |
Treasury ratio, end-2024 | 29.67% |
Treasury ratio after Kwangdong swap | 28.67% |
Treasury ratio, 31 Aug 2026 | 27.70% (16,105,105 shares) |
Jul 2023 buyback | KRW 10 bn |
Buyback authorisation outstanding | None found |
Statutory deadline to cancel pre-existing treasury shares or obtain shareholder approval for a holding plan | 5 Sep 2027 |
Analyst Conclusions
Guidance and expectations
- Daewoong Pharmaceutical FY2026 guidance (maintained May 2026): revenue about KRW 1.5 tn and OP about KRW 220 bn [S80].
Broker forecasts for Daewoong Pharmaceutical: consolidated FY2026 revenue KRW 1.71–1.73 tn and OP KRW 209–247 bn (DS/Kiwoom ranges; Kiwoom FY2026F OP KRW 247.0 bn as of Feb 2026, with later notes lower) [S81][S133].
H1 2026 actual: consolidated revenue KRW 826.3 bn (+10.6%) and OP KRW 90.3 bn (+17.7%) [S134].
Daewoong Co.: no guidance and no consensus.
Evolus: FY2026 revenue USD 327–337 m; 2028 target USD 450–500 m [S86].
Bull case
-
Sum-of-parts asymmetry. At current prices the listed stake in Daewoong Pharmaceutical (≈KRW 656 bn) more than covers Daewoong Co.'s ex-treasury market cap (≈KRW 645 bn). Investors get Daewoong Bio (FY2025 OP KRW 73.9 bn), the real estate and the subsidiaries for free (derived). Mandatory treasury-share action by September 2027 is a forcing event for value realisation.
-
Nabota operating leverage. Exports grew 54% in Q2 2026. With capacity tripling in 2027, a credible path to the KRW 500 bn 2030 target would roughly double the franchise from FY2025's KRW 228.9 bn at gross margins far above group average [S16][S24].
-
Litigation optionality. A favourable or limited appellate outcome in January 2027 would remove the largest overhang; the cumulative provision is only KRW 57.96 bn [S56b].
Bear case
-
Adverse Medytox ruling. Confirmation of the manufacturing and sales injunction would threaten Daewoong Pharmaceutical's largest product (about 21% of separate revenue) and could bring damages far above provisions (claim KRW 500.1 bn) [S57][S117].
-
Tariff and partner risk. The 15% US tariff from late September 2026 and the pull-forward in Q2 2026 point to softer H2 2026 and Q1 2027 export prints. Evolus's own margins are thin [S86][S14].
-
Governance discount persists. The holding company's FY2025 OP fell 7% even as the main subsidiary's grew 33%. Payout is about 5%, and treasury shares have been used for swaps with friendly parties rather than cancelled. The discount may be structural rather than cyclical [S10][S41][S42].
Catalysts and monitorables (next 12 months)
| Timing | Catalyst |
|---|---|
| Late Oct–Nov 2026 | Q3 2026 results (Daewoong Pharmaceutical, then Daewoong Co.): Nabota payback after pull-forward; ETC normalisation |
| End-2026 | cGMP certification of the new Nabota plant |
| Q4 2026 | CG Bio SPA (TA Associates) and any announced use of proceeds touching Daewoong Co. shares |
| January 2027 | Seoul High Court judgment in Medytox v. Daewoong |
| H1 2027 | Bersiporocin Phase 2 topline |
| March 2027 AGM | Treasury-share holding or cancellation plan (deadline Sep 2027); dividend decision |
| 2026–2027 | HanAll/Immunovant readouts: IMVT-1402 RA and CLE data in 2026; Graves' in 2027 |
| Ongoing | US tariff exemptions or adjustments; Evolus guidance updates |
Analyst verdict
Daewoong Co. is a holding company whose operating fundamentals and equity performance have moved in opposite directions. Operationally, the group has never been larger. Consolidated revenue passed KRW 2 tn in FY2025. Daewoong Pharmaceutical's operating margin reached 12.5%, and Q2 2026 set records on the back of a toxin franchise that has compounded at 57% a year since FY2019 [S10][S11][S24]. Nabota capacity triples in 2027, the pipeline has a credible first-in-class read-out in H1 2027, and Daewoong Bio remains a reliable cash generator.
The equity case does not rest on operations, however. It rests on three non-operating questions. The first is litigation: a January 2027 appellate ruling will decide whether the Nabota franchise operates free of a stayed injunction, and whether damages sit near the KRW 57.96 bn provision or closer to the KRW 500.1 bn claim. The second is trade: a 15% US tariff and a pull-forward of shipments make H2 2026 export comparisons unflattering. The third, and decisive for this security specifically, is governance. With 27.7% of shares in treasury, a payout of about 5%, a KCGS B rating and an owner-level asset sale running alongside the listed company, investors are entitled to doubt that value will reach minority holders.
The valuation already discounts a great deal. The stock trades below the market value of its Daewoong Pharmaceutical stake alone, at about 0.56x book on an ex-treasury basis and below 4x earnings. That points to a favourable risk-reward for patient investors, but only if the treasury-share decision required by September 2027 results in cancellation rather than further swaps with friendly parties.
Our view: fundamentally undervalued but catalyst-dependent. We would treat Daewoong Co. as an event-driven position sized for a binary January 2027 litigation outcome. The 2027 AGM's treasury-share resolution is the most important piece of evidence on whether the holding-company discount can narrow.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Since / tenure notes | Background |
|---|---|---|---|
Yoon Jae-chun | CEO (representative director) and Vice Chairman | Long-serving CEO (in role by 2017). Re-elected 2022 and March 2025 | Long-time Daewoong executive; previously also co-CEO of Daewoong Pharmaceutical (to 2023) |
Song Ki-ho | Inside director (Vice President) | Elected Mar 2023 | Daewoong Co. executive |
Park Seong-soo | Other non-executive director | Elected Mar 2025 | Co-CEO of Daewoong Pharmaceutical (see below) |
Lee Hoon-seok | Outside director | — | Corporate-law adviser, Bae, Kim & Lee (Taepyeong) |
Kang Young-chul | Outside director | — | Visiting professor, KDI School of Public Policy |
Choi In-hyuk | Outside director | Elected Mar 2023. | Former NAVER executive |
Yoo Seung-shin | Outside director | Elected Mar 2025 | Former CEO, Helixmith |
Woo Jong-soo | Outside director | Elected Mar 2025 | CEO, W Science; former Hanmi Pharmaceutical CEO |
Jeon Woo-bang | Standing statutory auditor | Re-elected Mar 2023 | Former head of planning and coordination at Daewoong Co.; ex-VP Daewoong Bio |
Yoon Jae-seung | Chief Vision Officer (CVO), group | Largest individual shareholder (11.64%) | Third son of the founder. Former chairman. A board seat at Daewoong Co. is not shown in retrieved sources |
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Lee Chang-jae | Co-CEO (marketing and domestic sales) | Co-CEO from 2022 per press; inside director since 2021; re-elected 2024 | Long-time Daewoong marketing executive |
Park Seong-soo | Co-CEO (R&D and overseas business) | Co-CEO since Mar 2024; inside director re-election proposed Mar 2026 | Joined 1999; master's degree from Seoul National University College of Pharmacy. Former head of the US subsidiary and of the Nabota division (from 2015). At his appointment he set market-cap targets of KRW 5 tn in 3 years and KRW 20 tn in 10 years |
Park Eun-kyung | Inside director; head of CH marketing | Since Mar 2024 | Former ETC marketing head |
Yoon Jun-soo | Head, Nabota business division | — | — |
Cho Young-min | Outside director | Mar 2024 | Professor of internal medicine, Seoul National University College of Medicine |
Kwon Soon-yong | Outside director | Mar 2025 | Professor, Seoul St. Mary's Hospital |
Choi In-hyuk, Choi Dae-hyun | Outside directors (proposed Mar 2026) | Mar 2026 | Former NAVER executive; CEO of KDB Capital/Investment affiliate |
Lee Kun-haeng | Standing auditor | Retired 26 Mar 2026 | Not a finance specialist (criticised in the press) |
Major Shareholders
| Holder | Stake (%) | Date |
|---|---|---|
Treasury shares | 27.70 | 31 Aug 2026 |
Yoon Jae-seung (CVO) | 11.64 | 2025–26 |
Daewoong Foundation | 9.98 | 2026 |
Yoon Jae-yong (founder's eldest son) | 7.01 | 2025 |
National Pension Service | 3.98 | 1 Oct 2025 (down from 5.01% in Apr 2025) |
Hananuri (ex-M Circle; Yoon Jae-seung-linked) | 1.77 | 2026 |
Kwangdong Pharmaceutical (from treasury-share swap) | about 1.0 | Dec 2025 |
U2Bio (from treasury-share swap) | 0.97 | Jan 2026 |
Bluenet | 0.26 | 2026 |
Yoon Su-min, Yoon Su-jin (twins) | 0.02 each | 2026 |
Major shareholder group total (as filed) | 38.04 | 31 Aug 2026 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Daewoong | FY2025 data (KRW Bn) |
|---|---|---|---|
Korean traditional pharma | Yuhan Corp. | No.1 by revenue; Leclaza lung-cancer royalties | Revenue 2186.6; OP 104.4 |
Korean traditional pharma | GC Biopharma | Plasma products (Alyglo in the US) | Revenue 1991.3; OP 69.1 |
Korean traditional pharma | Chong Kun Dang | Generics and in-licensing; Fexuclue co-promoter | Revenue 1692.4; OP 80.5 |
Korean traditional pharma | Kwangdong Pharmaceutical | Consumer and beverage-heavy; now a mutual shareholder | Revenue 1659.5; OP 31.0 |
Korean traditional pharma | Hanmi Pharmaceutical | Highest margins; Rosuzet; GLP-2 licensing to Lilly | Revenue 1547.5; OP 257.8 |
Korean traditional pharma | HK inno.N | K-CAB (tegoprazan), the main P-CAB rival to Fexuclue | Revenue above 1000; OP 110.9 |
Korean traditional pharma | Boryung | Oncology and cardiovascular | OP 65.1 |
Holding-company peer | Hanmi Science | Hanmi group holding company | Revenue 1356.8 |
Botulinum toxin (Korea) | Hugel | Botulax/Letybo; 47% margin; US launch with a hybrid direct model | Revenue 425.1; OP 201.6 |
Botulinum toxin (Korea) | Medytox | Litigant against Daewoong; weak profitability | OP 17.0 (6.9% margin; revenue about 246, derived) |
Botulinum toxin (global) | AbbVie (Botox), Ipsen/Galderma (Dysport), Merz (Xeomin), Revance (Daxxify) | Global leaders | — |
SGLT-2 | AstraZeneca (Forxiga), Boehringer/Lilly (Jardiance) and generics | Envlo is a local challenger | — |
Choline alfoscerate and generics | Chong Kun Dang and others | Daewoong Bio is a top-6 outpatient prescriber | — |
Peer Comparison FY2026
| Metric | Daewoong Co. | Daewoong Pharmaceutical | Yuhan | GC Biopharma | Hanmi Pharmaceutical |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 2,068.6 | 1,570.9 | 2,186.6 | 1,991.3 | 1,547.5 |
Revenue growth (%) | 6.8 | 10.4 | 5.8 | 18.5 | 3.5 |
Operating margin (%) | 12.7 | 12.5 | 4.8 | 3.5 | 16.7 |
Expensed R&D / revenue (%) | — | 11.5 | — | — | — |



